| http://www.w3.org/ns/prov#value | - Despite ongoing research and development and other costs for Levadex, including a likely postmarketing pediatrics study, company officials expect the transaction to be dilutive to 2013 earnings per share by approximately 7 cents on a GAPP basis and accretive to earnings per share by the second half of 2014, assuming the deal closes on schedule and Levadex is approved on or before its PDUFA date.
|
